M1412
HCPCSMet nsclc w/ egfr alk oth ab
Official HCPCS Level II long descriptor
Patients with metastatic nsclc with epidermal growth factor receptor (egfr) mutations, alk genomic tumor aberrations, or other targetable genomic abnormalities with approved first-line targeted therapy, such as nsclc with ros1 rearrangement, braf v600e mutation, ntrk 1/2/3 gene fusion, met ex14 skipping mutation, and ret rearrangement
HCPCS Level II code M1412 is maintained by CMS and is active in the current quarterly release.
Short descriptor
Met nsclc w/ egfr alk oth ab
Added to HCPCS: 2025-01-01
Nearby codes in M1
- M1404Pt ther clin trial
- M1405Pt w/ recur/prog
- M1406Pt lve prac
- M1407Pt died dur perf pd
- M1408Gmln brca bef dx ca
- M1409Recd gmln brca1/brca2 couns
- M1410No gmln brca1/brca2 couns
- M14111st ln ici no chemo
- M1413Pos pdl1 bef init ici tx
- M1414Med rsn no pdl1 bef 1st ther
- M1415No pos pdl1 bef ici ther
- M1416Pt rec hosp
- M1417Pt up to date cov
- M1418Med rsn not up to date cov
- M1419Pt not up to date cov
- M1420Complete ophthalmologic mvp
Where this code sits
Krasyn Codes for Chrome
Review coding suggestions beside a validated web workflow. Private pilot.
Request pilot accessSource
HCPCS Level II July 2026 quarterly update. Centers for Medicare & Medicaid Services (CMS), “July 2026 Alpha-Numeric HCPCS File” (HCPC2026_JUL_ANWEB_06172026.txt). Download the original file from cms.gov. Public domain (US Government work). Descriptors, billable flags and instructional notes on this page are reproduced from that file without modification. Krasyn adds no clinical guidance.